Imidaflea 40 mg Spot-on solution for Small Cats, Small Pet Rabbits & Small Dogs

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Ingredientes activos:

Imidacloprid

Disponible desde:

Chanelle Pharmaceuticals Manufacturing Limited

Código ATC:

QP53AX17

Designación común internacional (DCI):

Imidacloprid

Dosis:

40 mg/pipette

formulario farmacéutico:

Spot-on solution

tipo de receta:

LM: Licensed Merchant as defined in relevant national legislation

Área terapéutica:

imidacloprid

Estado de Autorización:

Authorised

Fecha de autorización:

2019-10-25

Ficha técnica

Health Products Regulatory Authority
31 January 2022
CRN00CD0F
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Imidaflea 40 mg Spot-on solution for Small Cats, Small Pet Rabbits &
Small Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 0.4 ml pipette contains:
​
ACTIVE SUBSTANCE:
​
​
Imidacloprid
​
40 mg
​
​
​
EXCIPIENTS:
​
​
Butylhydroxytoluene (E 321)
​
0.4 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Spot-on solution
A clear pale yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats, pet rabbits and dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For cats of less than 4 kg:
Prevention and treatment of flea (_Ctenocephalides felis_)
infestations.
For pet rabbits of less than 4 kg:
Treatment of flea infestations.
For dogs of less than 4 kg:
For the prevention and treatment of flea infestations and for the
treatment of biting lice (_Trichodectes canis_) on dogs.
Fleas on dogs are killed within one day following treatment.
One treatment prevents further flea infestation for four weeks on
dogs, three to four weeks on cats and up to one week on pet
rabbits.
4.3 CONTRAINDICATIONS
Do not treat unweaned kittens of less than 8 weeks of age.
Do not use on pet rabbits of less than 10 weeks of age.
Do not treat unweaned puppies of less than 8 weeks of age.
Do not use in known cases of hypersensitivity to the active substance
or to any of the excipients.
Health Products Regulatory Authority
31 January 2022
CRN00CD0F
Page 2 of 5
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Re-infestation from emergence of new fleas in the environment may
continue to occur for six weeks or longer after treatment
is initiated. More than one treatment may therefore be required,
depending on the level of fleas in the environment. To aid
reduction in environmental challenge, the additional use of a suitable
environmental treatment against adult fleas and their
developing stages is recommended. In order to reduce further the
environ